About Ab Initio Biotherapeutics

About company

Ab Initio Biotherapeutics operates as an antigen-discovery company. Its proprietary antigen discovery platform allows for targeting multi-transmembrane proteins such as GPCRs and facilitates antibody generation relevant to a wide array of therapeutic indications including neurological, cardiovascular, endocrine and gastrointestinal disorders.